GS 6637Alternative Names: GS-6637; GS-6673
Latest Information Update: 03 Oct 2015
At a glance
- Originator Gilead Sciences
- Class Drug withdrawal therapies
- Mechanism of Action Aldehyde dehydrogenase 2 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Drug abuse
Most Recent Events
- 22 Apr 2014 Phase-I clinical trials in Drug abuse in USA (unspecified route)